| Aes | adverse events |
| ALT | alanine transaminase |
| AST | aspartate transaminase |
| BC | breast cancer |
| CIPN | chemotherapy-induced peripheral neuropathy |
| ECOG | Eastern Cooperative Oncology Group |
| EORTC QLQ-CIPN20 | the European Organization for the Research and Treatment of Cancer-Chemotherapy-induced peripheral neuropathy 20 |
| HGWD | Huangqi Guizhi Wuwu decoction |
| IL-4 | interleukin-4 |
| iNOS | inducible nitric oxide synthase |
| ITT | intention-to-treat |
| nab-PTX | albumin-bound paclitaxel |
| NCI-CTCAE | Common terminology criteria for adverse events |
| PN | peripheral neuropathy; |
| PS | performance status; |
| PTX | paclitaxel |
| TNBC | triple negative breast cancer |
| TRAEs | treatment-related adverse events |
| ULN | upper limit of normal |